You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR GLYBURIDE; METFORMIN HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for GLYBURIDE; METFORMIN HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00035542 ↗ A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes. Completed Bristol-Myers Squibb Phase 3 2001-12-01 The purpose of this clinical research study is to see if Glucovance, a medication currently approved for use in adults with type 2 diabetes, can control type 2 diabetes safely and effectively in children 9 to 16 years of age.
NCT00035568 ↗ A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes Completed Bristol-Myers Squibb Phase 4 2002-02-01 The purpose of this clinical research study is to support earlier observations that Glucovance controls glucose levels after a mean, and improves overall glucose control better than metformin or glyburide therapy alone in adults with type 2 diabetes.
NCT00194896 ↗ Preferred Treatment of Type 1.5 Diabetes Completed GlaxoSmithKline N/A 2000-02-01 The purpose of this research was to test whether one treatment was superior over another in the management of type 1.5 diabetes. Specifically we tested recently diagnosed antibody positive type 2 diabetic patients to determine whether treatment with rosiglitazone results in greater preservation of beta cell function compared to treatment with glyburide.
NCT00194896 ↗ Preferred Treatment of Type 1.5 Diabetes Completed Seattle Institute for Biomedical and Clinical Research N/A 2000-02-01 The purpose of this research was to test whether one treatment was superior over another in the management of type 1.5 diabetes. Specifically we tested recently diagnosed antibody positive type 2 diabetic patients to determine whether treatment with rosiglitazone results in greater preservation of beta cell function compared to treatment with glyburide.
NCT00194896 ↗ Preferred Treatment of Type 1.5 Diabetes Completed University of Washington N/A 2000-02-01 The purpose of this research was to test whether one treatment was superior over another in the management of type 1.5 diabetes. Specifically we tested recently diagnosed antibody positive type 2 diabetic patients to determine whether treatment with rosiglitazone results in greater preservation of beta cell function compared to treatment with glyburide.
NCT00232583 ↗ Preservation of Beta-cell Function in Type 2 Diabetes Mellitus Completed University of Texas Southwestern Medical Center N/A 2003-11-01 The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone.
NCT00279045 ↗ Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide Completed GlaxoSmithKline Phase 3 2000-01-03 The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for GLYBURIDE; METFORMIN HYDROCHLORIDE

Condition Name

Condition Name for GLYBURIDE; METFORMIN HYDROCHLORIDE
Intervention Trials
Gestational Diabetes 5
Healthy 5
Gestational Diabetes Mellitus 3
Diabetes Mellitus, Non-Insulin-Dependent 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for GLYBURIDE; METFORMIN HYDROCHLORIDE
Intervention Trials
Diabetes Mellitus 16
Diabetes, Gestational 9
Diabetes Mellitus, Type 2 9
Hyperlipidemias 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for GLYBURIDE; METFORMIN HYDROCHLORIDE

Trials by Country

Trials by Country for GLYBURIDE; METFORMIN HYDROCHLORIDE
Location Trials
United States 112
United Kingdom 26
Canada 18
Germany 14
Italy 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for GLYBURIDE; METFORMIN HYDROCHLORIDE
Location Trials
Texas 8
Illinois 5
New York 4
California 4
Washington 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for GLYBURIDE; METFORMIN HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for GLYBURIDE; METFORMIN HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 5
Phase 3 6
Phase 2 1
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for GLYBURIDE; METFORMIN HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 18
Terminated 3
Unknown status 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for GLYBURIDE; METFORMIN HYDROCHLORIDE

Sponsor Name

Sponsor Name for GLYBURIDE; METFORMIN HYDROCHLORIDE
Sponsor Trials
GlaxoSmithKline 5
Actavis Inc. 3
University of Washington 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for GLYBURIDE; METFORMIN HYDROCHLORIDE
Sponsor Trials
Other 20
Industry 14
U.S. Fed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.